-
Mubritinib (TAK 165): Assay Workflow Guide
2026-09-23
Mubritinib (TAK 165) is most informative when used as a mitochondrial complex I probe rather than treated only as a historical HER2 inhibitor. This workflow guide connects dose selection, OXPHOS measurements, apoptosis profiling, and target-engagement controls for resistant AML and KSHV-positive PEL models.
-
Mubritinib–Albumin Recognition and Complex I Biology
2026-09-22
The reference study maps how Mubritinib (TAK 165) interacts with human serum albumin using complementary spectroscopic, biochemical, and molecular docking approaches. It identifies a moderately affine, site I-centered interaction that alters albumin fluorescence, structure, and esterase-like activity, providing pharmacokinetic context for research on this mitochondrial complex I inhibitor.
-
Toremifene Citrate: Applied Research Workflows
2026-09-21
Build reproducible estrogen-receptor experiments with Toremifene Citrate, from receptor-binding and MCF-7 proliferation assays to translational tumor-model planning. This guide emphasizes formulation, concentration selection, exposure timing, comparative controls, and troubleshooting that improve interpretation across breast cancer research workflows.
-
CHIR-99021 Workflow for Neural Differentiation
2026-09-21
CHIR-99021 (CT99021) provides selective GSK-3α/β inhibition for controlling pluripotency, differentiation, and Wnt/β-catenin signaling. This workflow connects pathway activation with exon-aware TRIM46 assays, helping researchers distinguish neuronal fate changes from post-transcriptional regulation during axon formation.
-
Dronedarone (Multaq): Atrial-Selective Research Strategy
2026-09-20
A mechanistic and translational framework for using Dronedarone (Multaq) in atrial fibrillation, atrial flutter, and cardiac arrhythmia pharmacology research, with emphasis on SK-channel evidence, assay design, and exposure-aware interpretation.
-
Verteporfin in YAP-TEAD Lineage Assays
2026-09-19
Verteporfin and CL 318952 are examined here as carefully controlled perturbations for linking phototoxicity, p62-dependent autophagy, and YAP-TEAD-regulated lineage commitment. The article translates recent super-enhancer research into assay-design decisions for ocular, cancer, and developmental models.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-18
Build a quantitative delivery workflow that separates mRNA uptake from productive EGFP translation in mammalian cells. Cy5 cargo tracking, ARCA capping, and 5-methoxyuridine modification make this reagent especially useful for comparing lipid nanoparticles, emulsions, and other mRNA delivery systems.
-
Diethylmaleate Workflows for Redox Research
2026-09-18
Diethylmaleate provides a practical way to perturb intracellular glutathione and test how redox buffering shapes ROS, GST activity, apoptosis, and chemical resistance. This workflow-focused guide translates insecticide-resistance evidence into controlled cell, toxicology, and organismal assays with built-in controls and troubleshooting strategies.
-
C8-HSL and Lung Cancer: PI3K/AKT/ERK Mechanism
2026-09-17
The 2026 FASEB Journal study identifies the bacterial quorum-sensing molecule C8-HSL as a direct promoter of lung cancer cell proliferation, migration, and invasion in H460 models. Its findings connect a microbial communication signal with PI3K/AKT/ERK activation and provide a mechanistic framework for investigating how lung microbiota may influence tumor behavior.
-
Epalrestat Workflows for Oxidative Stress Research
2026-09-17
Build reproducible Epalrestat experiments around polyol pathway inhibition, oxidative-stress readouts, and KEAP1/Nrf2 target engagement. The workflow connects diabetic neuropathy research with a mechanistically grounded Parkinson’s disease model while emphasizing formulation, controls, and troubleshooting.
-
FAISL Stabilizes FAK by Blocking Calpain-2 in TNBC
2026-09-16
The 2024 Advanced Science study identifies FAISL as a long non-coding RNA that stabilizes focal adhesion kinase (FAK) by preventing Calpain-2-mediated proteolysis, thereby promoting triple-negative breast cancer adhesion, survival, progression, and metastasis. Its combined transcriptomic, biochemical, cellular, and in vivo evidence defines a post-translational regulatory axis that may complement kinase-focused approaches to FAK biology.
-
Pterostilbene and Mitochondrial Quality in Fibroblast Aging
2026-09-15
Zhou et al. show that pterostilbene reduces senescence-associated changes in human dermal fibroblasts exposed to acute UVB-related oxidative stress or replicative aging. The study links these effects to improved mitochondrial morphology, membrane potential, respiration, and mitophagy, while nuclear staining can support complementary imaging and cytometric workflows.
-
Lyophilized mRNA-LNPs for Stable mAb Expression
2026-09-15
Wang et al. investigated lyophilized mRNA–lipid nanoparticle formulations as a way to reduce the cold-chain burden for in vivo monoclonal antibody expression. A formulation containing 5 mM Tris at pH 8 with 10% sucrose preserved key particle and biological properties after room-temperature storage for one month, supporting further development of dry mRNA-LNP dosage forms.
-
CCK-8 for Co-Exposure Cell Viability Studies
2026-09-14
This cck8 guide explains how Cell Counting Kit-8 converts cellular dehydrogenase activity into a practical viability readout for co-exposure research. It also translates findings from a cadmium–magnetic-field study into assay design, controls, and interpretation strategies.
-
Exercise Capacity Before Muscle Dysfunction in PH
2026-09-14
Zhang and colleagues show that exercise intolerance can emerge before measurable intrinsic skeletal muscle dysfunction in experimental pulmonary hypertension, shifting attention toward early cardiopulmonary impairment. Their strain- and severity-dependent rat design separates right-ventricular consequences from muscle structural, mitochondrial, and contractile changes, providing a useful framework for interpreting SU5416-based pulmonary hypertension models.